Evotec SE
NASDAQ:EVODrug Manufacturers - Specialty & Generic
-$0.02 today
- Market cap
- $518.56M
- Beta
- 1.30
- P/E (TTM)
- -4.2
- EPS (TTM)
- -$1.09
Volume 0.04M
Average 0.08M
EVO Operating Cash Flow
Cash generated by the company's core business operations during the period.
Evotec SENASDAQ: EVO
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow declines year over year
Q1 FY2026 operating cash flow of €2.18M (cash outflow) fell 93.1% year over year, behind the -37.4% change in trailing-twelve-month operating cash flow.
Context
- Operating cash flow amounted to 1.2% of revenue in FY2025, down 1.1 pp from a year earlier.
- Operating cash flow increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -93.1% toward the trailing-twelve-month pace of -37.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
EUR · from the cash flow
- Latest · FY2025
- (9.06M) EUR
- Year-over-year change
- -149.8%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (9.06M) | -149.8% |
| FY2024 | 2024-12-31 | 18.22M | -50.0% |
| FY2023 | 2023-12-31 | 36.44M | -82.3% |
| FY2022 | 2022-12-31 | 205.81M | +68.4% |
| FY2021 | 2021-12-31 | 122.24M | — |
Operating Cash Flow vs competitors
How EVO compares with its peers on the latest reported figures
- Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -37.4% is the lowest of 11, against a peer median of -8.0%.
- Operating cash flow amounts to 2.4% of revenue for EVO, versus a peer median of 11.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $287.95M USD | -4.2% | +15.9% | 11.5% | |
| LTM Sep 2026 | $249.32M USD | +54.0% | +28.3% | 275.5% | |
| LTM Sep 2026 | €167.54M EUR | +25.0% | +26.8% | — | |
| LTM Mar 2026 | $142.22M USD | -19.1% | +1.5% | 19.4% | |
| LTM Mar 2026 | $123.18M USD | -17.3% | -45.6% | 22.0% | |
| LTM Sep 2026 | $112.58M USD | +9942.4% | — | 41.8% | |
| LTM Sep 2026 | $57.51M USD | -20.3% | +114.4% | 9.2% | |
| LTM Feb 2026 | $55.79M USD | -16.8% | -16.6% | 4.7% | |
| LTM Mar 2026 | $26.88M USD | -11.7% | — | 4.0% | |
| LTM Mar 2026 | €17.85M EUR | -37.4% | — | 2.4% | |
| LTM Mar 2026 | $15.2M USD | +626.1% | +195.2% | 5.7% | |
| Peer median (excluding EVO) | — | -8.0% | +21.4% | 11.5% | |
Competitors are the stored peer set for EVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 215.51M | (175.66M) | (83.91M) | (196.08M) | (99.43M) |
| Depreciation & Amortization | 67.61M | 83.2M | 92.98M | 101.62M | 95.55M |
| Deferred Income Tax | 5.07M | 21.7M | 3.32M | 2.1M | 14.11M |
| Stock-Based Compensation | 7.81M | 9.92M | 9.63M | 5.04M | 0 |
| Change in Working Capital | (2.28M) | 105.29M | (9.94M) | (68.21M) | (58.4M) |
| Accounts Receivables | (48.03M) | (53.68M) | 0 | 0 | (27.6M) |
| Inventory | (11.65M) | (4.41M) | 0 | 0 | (9.18M) |
| Accounts Payables | 31.34M | 24.55M | 0 | 0 | (7.02M) |
| Other Working Capital | 26.06M | 138.83M | (9.94M) | (68.21M) | (14.61M) |
| Other Non-Cash Items | (171.47M) | 161.37M | 24.37M | 173.75M | 39.11M |
| Operating Cash Flow | 122.24M | 205.81M | 36.44M | 18.22M | (9.06M) |
| Capital Expenditures | (118.94M) | (181.35M) | (216M) | (132.24M) | (69.68M) |
| Acquisitions (Net) | (21.09M) | (83.82M) | (20.16M) | 42.78M | 213.76M |
| Purchases of Investments | (123.7M) | (355.82M) | (48.39M) | (29.39M) | (13.42M) |
| Sales of Investments | 27.25M | 205.17M | 260.36M | 35.67M | 38.87M |
| Other Investing Activities | (7.38M) | 3.03M | 8.22M | (2.78M) | 0 |
| Investing Cash Flow | (243.86M) | (412.8M) | (13.29M) | (71.19M) | 159.86M |
| Debt Repayment | 14.77M | (53.11M) | 84.6M | (152.07M) | (6.96M) |
| Common Stock Issued | 404.32M | 355K | 0 | 0 | (1.27M) |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (20.67M) | (5.39M) | (12.63M) | (9.35M) | (22.71M) |
| Financing Cash Flow | 398.43M | (58.15M) | 71.96M | (161.42M) | (30.93M) |
| Effect of Forex Changes | (66K) | (19.04M) | 644K | 9.87M | 28.46M |
| Net Change in Cash | 276.75M | (284.17M) | 95.75M | (204.52M) | 148.32M |
| Free Cash Flow | 3.29M | 24.46M | (179.56M) | (114.02M) | (78.74M) |
Evotec SE
NASDAQ:EVO
Intrinsic Alpha fair value
Locked
Current Price
$1.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.